Recipharm reaches agreement with LobSor Pharmaceuticals
Manufacturing of a proprietary treatment for advanced Parkinson’s disease
Advertisement
Recipharm and LobSor Pharmaceuticals announced the formation of a manufacturing agreement for LECIGON™. As part of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales. Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when LECIGON is produced for commercial sales.
This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.